{"entity":{"id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of HRS-4642 + AG in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT07232875 by Jiangsu HengRui Medicine Co., Ltd., with 588 participants planned, started 2025-11-21 and due to reach its primary completion in 2029-04. Interventions recorded: HRS-4642 + AG and HRS-4642 placebo + AG.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07232875","url":"https://clinicaltrials.gov/study/NCT07232875"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07232875","phase":"3","setting":"a Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial of HRS-4642 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Pancreatic Carcinoma Harboring KRAS G12D Gene Mutation","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT07232875","source":"https://clinicaltrials.gov/study/NCT07232875","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"7154b25ec7dfb354301ca79b81362cc85a458e24c6814e319e798aed82a52ed8","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-15","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":588,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-11-21","startedType":"actual","enrolled":588,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07232875/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}